Karuna Therapeutics, Inc. (NASDAQ:KRTX) Receives Consensus Rating of "Buy" From Analysts
Karuna Therapeutics, Inc. (NASDAQ:KRTX) Receives Consensus Rating of "Buy" From Analysts
Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) has been given a consensus rating of "Buy" by the fifteen analysts that are covering the company, MarketBeat Ratings reports. Thirteen research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $252.07.
據MarketBeat Ratings報道,卡魯納治療公司(納斯達克代碼:KRTX-GET評級)已被追蹤該公司的15位分析師一致給予“買入”評級。13位研究分析師已將該股評級為買入建議。在去年發佈了該股報告的券商中,1年目標價的平均水平為252.07美元。
KRTX has been the topic of several research reports. HC Wainwright increased their target price on Karuna Therapeutics from $160.00 to $320.00 and gave the stock a "buy" rating in a research report on Monday, August 15th. The Goldman Sachs Group raised their price objective on Karuna Therapeutics from $228.00 to $278.00 and gave the company a "buy" rating in a research report on Tuesday, August 9th. SVB Leerink raised their target price on Karuna Therapeutics from $170.00 to $270.00 and gave the company an "outperform" rating in a research note on Tuesday, August 9th. Royal Bank of Canada lifted their price target on Karuna Therapeutics from $292.00 to $293.00 in a research note on Thursday. Finally, Bank of America lifted their price target on Karuna Therapeutics from $160.00 to $261.00 and gave the stock a "buy" rating in a research note on Tuesday, August 9th.
KRTX已經成為幾份研究報告的主題。8月15日,週一,在一份研究報告中,HC Wainwright將KarunaTreateutics的目標價從160.00美元上調至320.00美元,並給予該股“買入”評級。高盛夫婦將卡魯納治療公司的目標價從228.00美元上調至278.00美元,並在8月9日(星期二)的一份研究報告中給予該公司“買入”評級。8月9日,SVB Leerink在一份週二的研究報告中將卡魯納治療公司的目標價從170.00美元上調至270.00美元,並給予該公司“跑贏大盤”的評級。加拿大皇家銀行在週四的一份研究報告中將卡魯納治療公司的目標價從292.00美元上調至293.00美元。最後,美國銀行將卡魯納治療公司的目標價從160.00美元上調至261.00美元,並在8月9日星期二的一份研究報告中給予該股“買入”評級。
Insider Transactions at Karuna Therapeutics
卡魯納治療公司的內幕交易
In other Karuna Therapeutics news, CFO Troy A. Ignelzi sold 16,500 shares of the company's stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $227.83, for a total value of $3,759,195.00. Following the completion of the sale, the chief financial officer now directly owns 24,970 shares in the company, valued at $5,688,915.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Karuna Therapeutics news, CFO Troy A. Ignelzi sold 16,500 shares of the company's stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $227.83, for a total value of $3,759,195.00. Following the completion of the sale, the chief financial officer now directly owns 24,970 shares in the company, valued at $5,688,915.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Laurie J. Olson sold 1,000 shares of the stock in a transaction on Monday, August 15th. The shares were sold at an average price of $267.59, for a total value of $267,590.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 62,500 shares of company stock worth $12,945,435. Company insiders own 16.20% of the company's stock.
在卡魯納治療公司的其他消息中,首席財務官特洛伊·A·伊格內爾齊在8月9日星期二的一筆交易中出售了16,500股公司股票。這隻股票的平均售價為227.83美元,總價值為3759,195.00美元。出售完成後,首席財務官現在直接擁有該公司24,970股,價值5,688,915.10美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過美國證券交易委員會網站。在卡魯納治療公司的其他消息中,首席財務官特洛伊·A·伊格內爾齊在8月9日星期二的一筆交易中出售了16,500股公司股票。這隻股票的平均售價為227.83美元,總價值為3759,195.00美元。出售完成後,首席財務官現在直接擁有該公司24,970股,價值5,688,915.10美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過美國證券交易委員會網站。此外,勞裏·J·奧爾森在8月15日(星期一)的一次交易中出售了1,000股董事股票。這些股票的平均價格為267.59美元,總價值為267,590.00美元。關於這次銷售的披露可以找到這裏。在過去三個月裏,內部人士出售了62,500股公司股票,價值12,945,435美元。公司內部人士持有該公司16.20%的股份。
Institutional Trading of Karuna Therapeutics
卡魯納治療公司的機構交易
Karuna Therapeutics Trading Up 0.2 %
卡魯納治療公司股價上漲0.2%
Shares of KRTX stock opened at $224.93 on Friday. The company has a market cap of $6.74 billion, a price-to-earnings ratio of -33.18 and a beta of 1.21. The stock has a 50 day simple moving average of $224.84 and a 200-day simple moving average of $155.55. Karuna Therapeutics has a 12-month low of $92.26 and a 12-month high of $278.25.
KRTX股票上週五開盤報224.93美元。該公司市值為67.4億美元,市盈率為-33.18倍,貝塔係數為1.21。該股的50日簡單移動均線切入位為224.84美元,200日簡單移動均線切入位為155.55美元。卡魯納治療公司的12個月低點為92.26美元,12個月高位為278.25美元。
Karuna Therapeutics (NASDAQ:KRTX – Get Rating) last announced its earnings results on Monday, August 8th. The company reported ($2.17) EPS for the quarter, missing analysts' consensus estimates of ($2.02) by ($0.15). The business had revenue of $5.28 million during the quarter. On average, equities analysts forecast that Karuna Therapeutics will post -8 earnings per share for the current fiscal year.
卡魯納治療公司(納斯達克代碼:KRTX-GET評級)上一次公佈收益結果是在8月8日星期一。該公司公佈了該季度每股收益(2.17美元),低於分析師普遍預期的(2.02美元)和(0.15美元)。該業務本季度的收入為528萬美元。股票分析師平均預測,卡魯納治療公司本財年每股收益將達到8美元。
About Karuna Therapeutics
關於卡魯納治療公司
(Get Rating)
(獲取評級)
Karuna Therapeutics, Inc, a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis.
卡魯納治療公司是一家臨牀階段的生物製藥公司,為患有精神和神經疾病的患者創造和提供變革性藥物。它的主要候選產品是KarXT,這是一種M受體的口服調節劑,正在進行第三階段臨牀試驗,用於治療精神分裂症患者的急性精神病,以及治療中樞神經系統障礙,如精神分裂症和精神病的陰性和認知症狀,以及治療與痴呆症相關的精神病。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Karuna Therapeutics (KRTX)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Declining Profits Challenge the CarMax Value Proposition
- 免費獲取StockNews.com關於卡魯納治療公司(KRTX)的研究報告
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat:回顧一週9/26-9/30
- 這是買入美光科技的難忘時刻
- 雷神工業走出谷底
- 利潤下降對CarMax價值主張的挑戰
Receive News & Ratings for Karuna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karuna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《卡魯納治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收對卡魯納治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。